Enumeral Biomedical Holdings Inc
Enumeral Biomedical — Investor Presentation (September 2015)
35 slides from Enumeral Biomedical's investor presentation, Sep 30, 2015
Slide 1: The Power of Human – Fall 2015
THE POWER of HUMAN™ Fall 2015
Slide 2: Forward Looking Statements
Forward Looking S tatements OTC QB: ENUM THIS PRESENTATION CONTAINS FORWARD - LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY’S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHARMACEUTICAL INDUSTRY . THE COMPANY MAKES NO REPRESENTATIONS ABOUT THE ACCURACY OF
Slide 3: Vision
Vision Leverage broad antibody diversity and human cell biology to develop cures for all cancer patients 3
Slide 4: Enumeral Opportunity
Enumeral Opportunity • Differentiated lead anti - PD - 1 antibody program as backbone for combination immunotherapy • Broad antibody pipeline against important immunotherapy targets • Translational science approach provides insights into target biology to drive combination therapy development • Stra
Slide 5: Immune system target complexity and combinations
Enumeral Opportunity Immune system target complexity: Breadth of antibody diversity and patient - centric insights provide for development of optimal combinations “Novel combinations with an anti - PD1 pathway backbone may produce better response rates in more tumor types with fewer side effects .”
Slide 6: Opportunity: Improve Cure Rate
Opportunity Improve Cure Rate 6 Sharma and Allison Cell 2015 ENUM translational science approach: differentiated insights drive development of combinations
Slide 7: Evolving Market Has Room For Innovators
Evolving Market H as R oom F or I nnovators * Q2 ‘15 revenues not reported in 10 - Q; Medicare reversed non - coverage decision for Blincyto : http:// www.fiercepharma.com/story/medicare - ponies - pay - extra - amgens - 178k - blincyto/2015 - 08 - 10 ** Bristol Myers Squibb; other data from SEC fil
Slide 8: Pipeline of Antibody Immunotherapies to Drive Combination Opportunities
Pipeline of Antibody Immunotherapies to Drive Combination Opportunities 8 Represents potential value inflection points *Assumes program partnered after preclinical efficacy studies; additional costs covered by partner; and additional capital raised or obtained through partnership. Leads Preclinical
Slide 9: Enumeral Advantage: The Power of Human
Enumeral Advantage: The Power of Human TM 9 function phenotype genomics Resolution of immunomodulatory targets on immune cells based on function Patient biopsy Differentiating insights into target biology Patient selection and optimal target combinations for development path After Tsioris et al 2015
Slide 10: Validation of Technology Platform
Validation of Technology Platform* 10 *Publications from laboratory of scientific founder, J. Christopher Love, Ph.D.
Slide 11: Recognition of Differentiated Approach
Recognition of Differentiated Approach • MERCK : c ollaboration with a leading immuno - oncology pharmaceutical company – Focused on using Enumeral's platform to interrogate the tumor microenvironment in colorectal cancer tissues to identify functional cellular responses to therapies being developed
Slide 12: Proprietary Broadly Enabling Platform
Proprietary Broadly E nabling P latform 12 84,672 50µm microwells • Microwell array chip and one - day process • Measures key parameters of function of individual immune cells from patient samples • Uniquely enumerates and rapidly identifies rare immune cells critical to responses • Validates target
Slide 13: Approach to Developing Differentiated Antibodies Starts with Diversity
Approach to Developing Differentiated Antibodies Starts with Diversity • Enumeral antibody discovery results in exceptional diversity * • Proprietary compositions of matter of Anti - PD - 1 antibodies • Potential for strong IP position • Breadth of diversity: keys to unlocking the target physiology
Slide 14: Next Pipeline Programs: TIM-3 and LAG-3
Next Pipeline Programs: TIM - 3 and LAG - 3 • Enumeral antibody discovery results in exceptional diversity * • Diversity critical for complex target physiology 14 LAG - 3: 102 Sequences 40 Families TIM - 3: 124 Sequences 42 Families *Based on ENUM evaluation of published literature
Slide 15: PD-1 Overview
PD - 1 Overview • Proven target commercially and clinically • Backbone of future immuno - oncology combination therapies • Mechanism of action of PD - 1 - targeted drugs poorly understood – Reported overall response rates (ORR): 32% for Opdivo and 24% for Keytruda in advanced metastatic melanoma – D
Slide 16: PD-1 and The Immune Control of Cancer
PD - 1 and The Immune Control of Cancer T cells and control of cancer: • Activated T cells lock onto tumor cells in order to kill them • T umor cells suppress the immune system via the PD - L1 protein binding to PD - 1 on T cells 16 Approved anti - PD - 1 therapies disrupt PD - L1 binding to PD - 1
Slide 17: Lead Program: Potential Allosteric PD-1 Modulator
Lead Program: Potential Allosteric PD - 1 Modulator 17 Current anti - PD1 agents allow for T cell activation; disrupt PD - L1 binding to PD - 1 PD - L1 engagement results in T cell inhibition; tumor cell protected ENUM anti - PD1: novel epitope and PD - L1 independent binding; IL - 2R autocrine acti
Slide 18: Lead Program: Reversal of PD-L1 Suppression in Cell-Based Assays
Lead Program: Reversal of PD - L1 Suppression in Cell - Based Assays 18 IFNg secretion (relative to control) N = 5 repetitions for each candidate/condition • PBMC - based assay to determine mAb’s ability to disrupt functional suppression by PD - L1 • ENUM candidates compared with : – Activation only
Slide 19: D - H C + L C D - H C + L C
D 4 - H C 3 + L C 1 D 4 - H C 1 + L C 3 D 4 - H C 3 + L C 3 C 8 - H C 1 + L C 1 C 8 - H C 1 + L C 3 C 8 - H C 2 + L C 1 N i v o - I g G 4 h I g G 4 - H C A 2 4 7 0 5000 10000 MLR Donor 337+23 (IFNy) I F N y ( p g / m l ) 10 ug/ml 1 ug/ml 0.1 ug/ml 0.01 ug/ml Antibody concentration Antibody concentra
Slide 20: Differentiated PD-1 Antagonist with Potential Allosteric Mechanism
Differentiated PD - 1 Antagonist with Potential Allosteric Mechanism 20 PD - L1 engagement results in T cell inhibition Hypothesis: approved PD - 1 agents allows for T cell activation; T cell – Tumor cell interaction altered when PD - L1 interaction disrupted Hypothesis: PD - 1 blockade with ENUM al
Slide 21: Enhanced T Cell Immunomodulation: Potential Clinical Implications
Enhanced T Cell Immunomodulation: Potential Clinical Implications • Monotherapy : Differentiated mechanism of action; potential higher initial response rate and durable responses • Potential to treat PD - 1 refractory or relapse patients (non - responders) • Potential synergistic Rx: with TIM - 3 bl
Slide 22: Translational Science Platform Drives Antibody Development
Enumeral Advantage: Translational Science Platform Drives Antibody Development • Proprietary bioinformatics capability to define target correlation with disease • Define cell types on which the target is expressed • Define subsets of functional immune cells that express the target in biopsy from int
Slide 23: Enumeral Pathway Annotation Informs Indication Selection
Proprietary ‘ Enumeral Pathway Annotation’ (EPA) I nforms I ndication Selection 23 EPA Lymphoid index (inc. PD-1) EPA Myeloid index (inc. TIM3) EPA TIM3-index (3 gene index) Solid Tumor #1 Solid Tumor #1 Solid Tumor #2 Solid Tumor #5 Solid Tumor #2 Solid Tumor #1 Solid Tumor #2 Solid Tumor #3 Solid
Slide 24: Translational Science Platform Provides Differentiated Insights: Melanoma
Translational Science Platform Provides Differentiated Insights Into Target Biology 24 Target validation in human melanoma sample h ypothesis: TIGIT may be key checkpoint target for melanoma treatment Differentiated insights into target biology Enables indication selection and development path Cytok
Slide 25: Translational Science Platform Provides Differentiated Insights: Colorectal
Translational Science Platform Provides Differentiated Insights Into Target Biology 25 Platform uniquely identifies rare events at high resolution: identification of TIM - 3 expression on non - T cells suggests combination approach Differentiated insights into target biology Enables development of p
Slide 26: Indication Selection Guided by Translational Science Platform
Indication Selection Guided by Translational Science Platform Program NSCLC TNBC Gastric Head & Neck Rectal Renal CC ORR (from Label) 15% Opdivo (squamous) 1 ORR (reported from clinical trials ) 19.4% Keytruda 2 18.5% Keytruda 3 32% AsiaPacific 30% Rest of World Keytruda 4 18.2% Keytruda 5 CRC (incl
Slide 27: Clinical Trial Plans Support Testing of Multiple Combinations
Clinical T rial P lans S upport Testing of Multiple Combinations 27 IND TIM 3 Phase 1 PD 1 Phase 1 IND PD1 Allosteric TIM3 PD1 Vaccine or Targeted Rx Checkpoint blockade improves efficacy of other modalities PD1 TIM3 PD 1 Allosteric Phase 2 : Monotherapy IND PD 1 Allosteric Phase 1 Treat relapse and
Slide 28: Strong Intellectual Property Position
Strong Intellectual Property Position • Exclusive worldwide license with MIT/Harvard for platform technology – 6 issued patents in US and 29 issued in international jurisdictions – 26 pending patent applications (US & International) • Patents covering compositions of matter and methods – 4 a pplicat
Slide 29: Strategy: Development Partnerships
Strategy: Development Partnerships • Out - license or co - develop antibodies for combination with oncology drugs – Chemotherapy, targeted therapy, vaccines, radiation • Pipeline and translational approach drive combination development – TIM - 3, LAG - 3, OX40, VISTA, TIGIT, CD39, CD66a • Retain lon
Slide 30: Opportunities for New Entrants and Co-Development Partnerships
Opportunities for New Entrants and Co - Development Partnerships 30 Only companies with disclosed clinical I/O programs against the targets listed are shown**; bold indicate ENUM targets. *Source: Defined Health, presentation at Sachs I/O Investment Forum, Chicago May 2015. **Based on publicly avail
Slide 31: Projected Growth Driven by Checkpoint Inhibitors and Costimulators
Projected Growth Driven by Checkpoint Inhibitors and Costimulators 31 C heckpoint inhibitors and costimulators Strong interest in new immunotherapies among big pharma companies, especially for antibody approaches – Merck, Bristol Myers Squibb, AstraZeneca and Roche are leading development
Slide 32: Experienced Leadership Team
Experienced Leadership T eam 32 John J. Rydzewski Executive Chairman, Co - Founder, Director Arthur H. Tinkelenberg, Ph.D. President & CEO, Co - Founder, Director Cokey Nguyen, Ph.D. Vice President, Research & Development Isabel Chiu, Ph.D. Vice President, Translational & Clinical Sciences Kevin G.
Slide 33: Accomplished Board of Directors
Accomplished Board of Directors 33 John J. Rydzewski Executive Chairman, Co - Founder, Director Arthur H. Tinkelenberg, Ph.D. President & CEO, Co - Founder, Director Barry Buckland, Ph.D. Co - Founder, Chairman, Scientific Advisory Board Robert J. Easton Director Allan Rothstein Director Paul J. Sek
Slide 34: Financials & Capitalization
Financials & Capitalization Common Shares Outstanding 51,699,507 Warrants Outstanding* 24,803,409 Options Outstanding** 3,521,336 Burn Rate , Q2 ’15 ($2.6M) Total Debt $0.0M Cash, Cash Equivalents and Marketable Securities** $8.4M 34 OTC QB: ENUM Price: $0.44 Market Cap (9/25/2015) $22.7M Enumeral i
Slide 35: The Power of Human – Contact
THE POWER of HUMAN™ Arthur H. Tinkelenberg, Ph.D. President and CEO [email protected] 617 - 500 - 2647
Enumeral Biomedical Holdings — Investor Presentation (September 2015) on 6ix